Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry.

Manaswini Pillai,Simon Erridge,Lara Bapir,Martha Nicholas,Nishaanth Dalavaye,Carl Holvey,Ross Coomber,Daniela Barros,Urmila Bhoskar,Gracia Mwimba,Kavita Praveen,Chris Symeon,Simmi Sachdeva-Mohan,James J Rucker,Mikael H Sodergren

Expert review of neurotherapeutics（2022）

引用 1|浏览10

暂无评分

摘要

Associated improvements in HRQoL were observed in patients who initiated CBMP therapy. Adverse events analysis suggests acceptability and safety up to 6 months. This study may inform randomized placebo-controlled trials, required to confirm causality and determine optimal dosing.

查看译文

关键词

Cannabidiol,PTSD,medical cannabis,post-traumatic stress disorder,tetrahydrocannabinol

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要